APP21 transgenic rats develop age-dependent cognitive impairment and microglia accumulation within white matter tracts by Weishaupt, Nina et al.
Western University 
Scholarship@Western 
Anatomy and Cell Biology Publications Anatomy and Cell Biology Department 
8-28-2018 
APP21 transgenic rats develop age-dependent cognitive 
impairment and microglia accumulation within white matter tracts 
Nina Weishaupt 
Vulnerable Brain Laboratory, Department of Anatomy and Cell Biology, Schulich School of Medicine and 
Dentistry, University of Western Ontario 
Qingfan Liu 
Vulnerable Brain Laboratory, Department of Anatomy and Cell Biology, Schulich School of Medicine and 
Dentistry, University of Western Ontario 
Sheojung Shin 
Vulnerable Brain Laboratory, Department of Anatomy and Cell Biology, Schulich School of Medicine and 
Dentistry, University of Western Ontario 
Ramandeep Singh 
Vulnerable Brain Laboratory, Department of Anatomy and Cell Biology, Schulich School of Medicine and 
Dentistry, University of Western Ontario 
Yuksel Agca 
Department of Veterinary Pathobiology, College of Veterinary Medicine, University of Missouri 
See next page for additional authors 
Follow this and additional works at: https://ir.lib.uwo.ca/anatomypub 
 Part of the Anatomy Commons, and the Cell and Developmental Biology Commons 
Citation of this paper: 
Weishaupt, Nina; Liu, Qingfan; Shin, Sheojung; Singh, Ramandeep; Agca, Yuksel; Agca, Cansu; Hachinski, 
Vladimir; and Whitehead, Shawn Narain, "APP21 transgenic rats develop age-dependent cognitive 
impairment and microglia accumulation within white matter tracts" (2018). Anatomy and Cell Biology 
Publications. 216. 
https://ir.lib.uwo.ca/anatomypub/216 
Authors 
Nina Weishaupt, Qingfan Liu, Sheojung Shin, Ramandeep Singh, Yuksel Agca, Cansu Agca, Vladimir 
Hachinski, and Shawn Narain Whitehead 
This article is available at Scholarship@Western: https://ir.lib.uwo.ca/anatomypub/216 
RESEARCH Open Access
APP21 transgenic rats develop age-
dependent cognitive impairment and
microglia accumulation within white matter
tracts
Nina Weishaupt1†, Qingfan Liu1†, Sheojung Shin1, Ramandeep Singh1, Yuksel Agca2, Cansu Agca2,
Vladimir Hachinski3 and Shawn Narain Whitehead1*
Abstract
Background: Most of the animal models commonly used for preclinical research into Alzheimer’s disease (AD)
largely fail to address the pathophysiology, including the impact of known risk factors, of the widely diagnosed
sporadic form of the disease. Here, we use a transgenic rat (APP21) that does not develop AD-like pathology
spontaneously with age, but does develop pathology following vascular stress. To further the potential of this novel
rat model as a much-needed pre-clinical animal model of sporadic AD, we characterize APP21 transgenic rats
behaviorally and histologically up to 19 months of age.
Methods: The open field test was used as a measure of activity; and the Morris water maze was used to assess
learning, memory, and strategy shift. Neuronal loss and microglia activation were also assessed throughout the
brain.
Results: APP21 transgenic rats showed deficits in working memory from an early age, yet memory recall
performance after 24 and 72 h was equal to that of wildtype rats and did not deteriorate with age. A deficit in
strategy shift was observed at 19 months of age in APP21 transgenic rats compared to Fischer wildtype rats.
Histologically, APP21 transgenic rats demonstrated accelerated white matter inflammation compared to wildtype
rats, but interestingly no differences in neuron loss were observed.
Conclusions: The combined presence of white matter pathology and executive function deficits mirrored what is
often found in patients with mild cognitive impairment or early dementia, and suggests that this rat model will be
useful for translationally meaningful studies into the development and prevention of sporadic AD. The presence of
widespread white matter inflammation as the only observed pathological correlate for cognitive deficits raises new
questions as to the role of neuroinflammation in cognitive decline.
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Background
To study the impact of the prodromal phase of Alzhei-
mer’s disease (AD), including the role of potential risk
factors in the progression of AD, novel preclinical
models are needed. As rodents do not develop signs of
AD naturally, different models have been created to ex-
hibit AD-like pathology, including the introduction of
amyloid fragments [1], toxins [2–4], and one or more
transgenes [5, 6]. Transgenic mice have been widely used
to model pathological correlates of AD, however, most
do not fully recapitulate the pathological and behavioral
components of AD and therefore have demonstrated
limited translational success [5–7]. A small number of
transgenic rat models for the study of AD have only
more recently become available [8, 9]. Rats may be more
valuable models than mice as they are both physiologic-
ally closer to humans [7], and are better than mice at
performing complicated cognitive tasks, such as those
requiring complex executive functions like strategy shift
[10], a behavioral precursor to memory impairment
more commonly associated with AD.
Here, we use behavior and histology, to characterize the
transgenic (APP21) rat model for its pre-clinical use in
studying mild cognitive impairment (MCI) and the
early-phase of sporadic AD. These transgenic rats were cre-
ated on a Fisher 344 background and express the human
amyloid precursor protein (APP) gene with both Swedish
and Indiana mutations [11]. As reported previously, these
rats do not develop histological hallmarks of AD spontan-
eously when aged up to 30 months [12]. They do, however,
develop histopathological signs of AD when challenged
with brain extract from AD patients injected intracerebrally
[12], or when experimental hydrocephalus is induced [13].
To date, behavioral and histological characterizations of the
APP21 transgenic rat are lacking. Therefore, in the present
study, we compare the behavior and histopathology of the
APP21 transgenic rat to wildtype Fischer rats over the
course of 19 months to establish a solid basis for future ex-
perimentation using this model. We hypothesized that
APP21 transgenic rats would demonstrate enhanced
age-related learning and memory deficits due to the patho-
genic human mutation expression. We observed deficits in
executive function and a developing neuroinflammatory
phenotype, with a focus on white matter tracts, suggesting
that APP21 transgenic rats may closely model the clinical
phase of mild cognitive impairment (MCI) [14, 15]. There-
fore, APP21 rats may have unique potential for translation-
ally meaningful research into risk factors and preventative
approaches to non-familial forms of dementia [16].
Methods
Animals and experimental groups
All animal studies have been approved by local Univer-
sity Animal Use Committee (UWO 2014-016) and are
compliant with the Canadian Council of Animal Care.
Six cohorts of male Fisher 344 rats (total of 40) were
bred in-house and aged to either 15 or 19 months (m),
each cohort consisting of age-matched Fisher 344 wild-
type (WT) and APP21 transgenic rats (TG). APP21 rats
express the human APP gene with both the Swedish and
Indiana mutations known to cause familial AD in
humans [11]. Homozygous founder breeding pairs were
kindly provided by Dr. Yuksel Agca (University of Mis-
souri, [11]). Presence of the transgene in all offspring
from homozygous pairings was confirmed by PCR. WT
and TG rats underwent a behavioral testing schedule as
shown in Fig. 1. Four additional rats (two WT and two
TG) were euthanized at 3 months for histological pro-
cessing of their brains. All rats were male, group housed,
maintained at a 12 h/12 h light/dark cycle, and fed ad
libitum.
Behavioral assessments
Open field
Rats were allowed to freely move in an Open Field Test
Arena (MedAssociates Inc., St. Albans, USA, 45 cm ×
45 cm) for 10 min at 3 months of age. Movement in the
arena was automatically tracked by three 16-beam infra-
red arrays and recorded by Activity Monitor Software
(MedAssociates Inc.). The ambulatory time and the
number of rears were used to assess the rats’ activity
level. The test was repeated at 19 months of age using
ANY-maze software-based tracking from a video
camera.
Morris water maze
Spatial learning, memory, and strategy shift ability, three
distinct cognitive domains often impaired in individuals
with MCI or early dementia, were evaluated. Rats were
introduced into a circular pool, 146 cm in diameter,
filled with water rendered opaque by water-soluble, non-
toxic, black paint.
Spatial learning: at 3 months of age, rats were trained
(four trials per day for four consecutive days) to swim to a
submerged, invisible platform (Fig. 1b). For each learning
trial, rats were introduced in the pool from a different
quadrant and were given 60 s to find the platform (loca-
tion remained the same). Once on the platform, rats were
left in place for 30 s to allow for spatial orientation based
on light/dark cues on the walls around the pool. Rats that
did not reach the platform within the time limit were
guided to the platform by the experimenter. At the
10-month, 13-month, and 16-month time points, 8
re-acquisition trials were conducted on 2 consecutive days
for learning of a new platform location (platform location
remained the same across the 16 trials, Fig. 1b).
Re-acquisition trials were run following the same protocol
as learning trials in blocks of four trials. A second block of
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four trials was started 50 min after each rat’s fourth learn-
ing trial on the same day (Fig. 1c). Thus, working memory
could be assessed within blocks of four trials (30 s plat-
form orientation time equals the delay between four con-
secutive trials), short-term memory could be assessed
between blocks of four trials (50 min delay between trial 4
and trial 5, and between trial 12 and 13) and 24-h memory
could be assessed between the first and second day of
re-acquisition (trial 9).
Long-term memory recall: memory retention was
tested by a 30 s spatial probe trial, 3 days following the
last learning trial (Fig. 1b, c), where the platform was re-
moved from the pool. All rats were released from the
same location.
Strategy shift: at 19 months of age, the rats’ ability to
shift strategies from 1 day to the next was tested using a
modified re-acquisition paradigm. On day 1, rats re-
ceived two blocks of four learning trials to learn a new
platform location and establish a memory of the loca-
tion. On day 2, the platform location changed again and
rats were given two blocks of four learning trials to learn
the new platform location (Fig. 1d). This way, rats were
asked to establish an accurate memory of a specific plat-
form location on day 1, and then to recognize that the
old location was no longer valid, and respond with a
shift to a search strategy for a new location on day 2. At
the end of this assessment, all rats underwent four cued
trials, in which the platform was rendered visible by a
yellow marker that reached above the water surface. The
platform location was changed for each of these cued
trials.
Morris water maze analysis: for all trials, the rats’
movements within the pool were tracked using a web-
cam and analyzed by ANY-maze software (Stoelting Co.,
Wood Dale, USA). Learning and re-acquisition were
assessed by plotting the latency to reach the platform,
while probe trial performance was measured by calculat-
ing the percentage of time the rat spent in the quadrant
in which the platform was previously located (target
quadrant). In addition to these automated out-reads, we
manually performed a swim pattern analysis and
expressed the percentage occurrence of “direct swim”
(DIM), “chaining” (CSS), and search strategy, for each
rat [17, 18].
Perfusion and tissue preparation
Rats were euthanized with an overdose of pentobarbital
(Euthanyl), transcardially perfused with 10 mM
phosphate-buffered saline (PBS) containing 5000 IE/L hep-
arin (Pharmaceutical Partners of Canada, Richmond Hill,
ON, Canada) followed by 4% paraformaldehyde. Brains
were harvested, post-fixed in 4% paraformaldehyde for
Fig. 1 Overview of behavioral testing. Rats were assessed in the open field (OF) and in the Morris water maze (MWM) at different ages (a). The
initial water maze protocol (b) consisted of 4 days of acquisition trials. Subsequent testing was done by more intensive training on two
acquisition days (c). At 19 months of age, rats underwent a unique water maze protocol aimed at testing their mental flexibility in a strategy shift
paradigm over two consecutive days (d)
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24 h, and subsequently transferred into a 30% sucrose solu-
tion. Each brain was then sectioned into 10 series of
30-μm-thick sections, collected free-floating in cryoprotect-
ant (30% sucrose, 30% ethylene glycol in 10 mM PBS), and
stored at − 20 °C.
Histology immunohistochemistry
Free-floating sections were first incubated in 1% H2O2 in
0.01 M PBS for 15 min. Sections were then blocked at
room temperature in a solution containing 10% horse
serum and 0.01 M PBS for 1 h. Sections were then incu-
bated overnight at 4 °C in either mouse anti-NeuN (1:1000,
EMD Millipore, Etobicoke, ON, Canada), rabbit anti-IBA-1
(1:1000, Wako Chemicals USA Inc., Richmond, VA, USA),
or mouse anti-OX-6 (1:1000, BD Pharmingen, Mississauga,
Canada) primary antibodies. Following 3 × 10 min washes
in 0.01 M PBS, sections were incubated in biotinylated
anti-mouse secondary antibody (1:2000, Vector Laborator-
ies Inc., Burlingame, CA, USA) for 1 h at room temperature
and then incubated in 2% avidin-biotin complex solution
(Vectastain Elite ABC Kit, Vector Laboratories, Inc., Burlin-
game, CA, USA) for 1 h at room temperature. Finally, sec-
tions were incubated in 0.05% 3,3′-diaminobenzidine
tetrahydrochloride (DAB; Sigma) and 1% H2O2 for approxi-
mately 1–3 min at room temperature. Sections were dehy-
drated in ascending concentrations of alcohol, submerged
in xylene, and then mounted with Depex mounting
medium (Depex, BDH Chemicals, Poole, UK). Mounted
brain sections were also processed with Luxol fast blue to
detect changes in myelin content [19].
Histological analyses
Investigators were blinded to all histological analysis and
measurements. Stained sections were analyzed using a
Nikon Eclipse Ni-E upright microscope with a Nikon DS
Fi2 color camera head (NIS Elements Imaging, Nikon In-
struments, Melville, NY, USA). All integrated density mea-
surements were calculated using ImageJ software (NIH
Software) and were averaged from three adjacent tissue sec-
tions per region per rat. Integrated density measurements
were made within white matter tracts and the cerebral cor-
tex of IBA-1 (general microglia marker) immunostained
brain sections. Integrated density measurements were made
within white matter tracts for OX-6 (marker for activated
microglia) immunostained sections. OX-6 immunoreactiv-
ity was assessed in the cerebral cortex of each rat and was
rated on a 0–3 point scale. Neuron loss was assessed using
NeuN cell counts from both dorsal and lateral cortices (left
and right) from three adjacent sections per rat. Total NeuN
counts within the regions of interest were calculated using
particle analysis within Nikon Elements software. Integrated
density measurements were made from gray-scale con-
verted Luxol fast blue photomicrographs from three adja-
cent tissue sections per region per rat.
Statistical analysis
The number of analyzed rats (n) included in individual
analyses varies throughout this study primarily due to
mortality for a variety of health issues not related to the
experimentation (17.5%). All comparisons among groups
at different time points were analyzed using two-way
ANOVA followed by Sidak’s multiple comparisons where
indicated. Open field activity was compared using a
Mann–Whitney test. Histology was analyzed using
two-way ANOVA followed by Tukey’s post-hoc tests.
Data are expressed as group mean ± SEM and n values
are indicated on individual graphs or within graph bars.
Results
TG rats take longer for spatial learning due to a working
memory deficit
All rats were given 16 acquisitions to learn the location of
a submerged platform in the Morris water maze task. WT
and TG rats were able to learn the location to a similar ex-
tent by the end of the acquisition period; however, TG rats
did not learn the platform location as quickly as WT rats.
This was seen in a consistent difference in trial latencies
between the genotypes in the first eight trials of each ac-
quisition session (p = 0.0006, two-way ANOVA, Fig. 2a),
while swim speeds were comparable between the two
groups across learning trials (Additional file 1: Figure S1).
To assess the rats’ working memory performance, the
average latency of trials 2–4 was plotted at each point in
time when the rats were introduced to a new platform lo-
cation. Trial 1 was excluded as no memory is involved in
finding the new platform location in the first trial. Trial 5
was excluded for this analysis as it was conducted 50 min
or 24 h (at 3 m of age) after the first set of four trials. A
two-way ANOVA across all time points revealed a signifi-
cant effect of genotype (p = 0.0003, Fig. 2b), with TG rats
consistently taking longer to find the platform than WT
rats. Sidak’s multiple comparisons revealed a significant
difference only at the 3-month time point (p < 0.05). As a
two-way ANOVA does not allow the data from rats that
did not reach the 19 months endpoint to be included, we
also looked at individual time points using a Mann–Whit-
ney test and increased statistical power. Using this
method, a significant difference between the two groups
was still evident at 10 months of age (20.02 ± 15.13, n =
12, vs. 10.65 ± 7.90, n = 11, p = 0.046).
Short-term memory was assessed by comparing trial
latencies for trial 5. Trial 5 requires the rats to remem-
ber what they learned 50 min before in four consecutive
acquisition trials. As trial 5 was conducted 24 h after
trial 4 at 3 months of age, this assessment was only done
from 10 months of age onwards. Similar to the working
memory result, TG rats took consistently longer to find
the platform in trial 5 than WT rats across all time
points (21.86 vs. 6.89 at 10 months, 17.99 vs. 3.75 at
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13 months, 28.53 vs. 8.86 at 16 months, 15.07 vs. 7.02 at
19 months, p = 0.0058, Two-way ANOVA, Fig. 2c). A
Sidak’s multiple comparison test revealed a significant
difference between the groups at the 16 m time point (p
< 0.05). The 24 h memory between trials 8 and 9 was
likewise assessed, with no significant differences between
the genotypes in latencies in trial 9 (Fig. 2d).
In conclusion, TG rats took longer to build spatial mem-
ory due to working and short-term memory deficits when
compared to their WT counterparts. This was confirmed
by a swim pattern analysis, which showed that WT rats
have significantly more “direct swim” patterned trials than
TG rats in trials 2–5 (p = 0.0392, two-way ANOVA,
Fig. 2e); an indicator for accurate memory.
TG rats have no long-term memory recall deficit
The rats’ 3-day memory was assessed in a probe trial,
where the time spent in the target quadrant was
assessed. Both genotypes performed equally (Fig. 3), and
their performance did not decrease up to 16 months of
age, the last time point that long-term memory was
assessed. Most values show, however, that both rat
groups performed only 5 to 10 percentage points above
chance (25%), indicating that memory recall was not as
robust as often seen in young healthy rats [20].
TG rats demonstrate a deficit in the ability to shift
strategy
At 19 months of age, all rats performed a strategy shift
water maze task. As before, they were asked to learn a
new platform location in two blocks of eight trials on
day 1, but this time the platform location was unexpect-
edly changed on day 2. While TG rats (16.22 s ± 11.63)
were on average 5 s slower than WT counterparts
(11.25 s ± 6.96) at finding the platform during trials 2–4
on day 1, they were running on average almost 15 s be-
hind WT rats on day 2 with the changed platform loca-
tion (27.46 ± 17.11 vs. 12.77 ± 6.84, p = 0.0131, two-way
Fig. 2 Performance in Morris water maze acquisition across age. To assess how fast TG and WT rats learned a new platform location in the MWM
task, the average latency to find the platform in the first eight learning trials was calculated at each age time point (a). TG rats were significantly
slower in finding the platform than WT rats across time points. To assess working memory performance, the latency to find the platform in trials
2–4, which were 30 s apart, was compared between genotypes (b). TG rats demonstrated worse performance in working memory than WT rats.
Comparing performance in trial 5 was used as a measure of memory as all rats had completed four learning trials 50 min prior (c). A significant
effect of genotype was observed in trial 5, and TG rats performed significantly worse at 16 months of age. 24-h memory performance in trial 9
was not significantly different between genotypes (d). Swim pattern analysis showed that TG rats exhibited the “direct immediate” swim pattern
(DIM), a sign of accurate memory, significantly less often than WT rats in trials 2–5 (e). Graphs show mean ± SEM. One asterisk indicates p < 0.05,
three asterisks indicate p < 0.001 (two-way ANOVA results indicated beside genotype and results of Sidak’s multiple comparisons indicated
on bars)
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ANOVA effect of genotype, Fig. 4a). TG rats were
thereby significantly slower in shifting focus to the new
platform location than WT rats (p < 0.05, Sidak’s mul-
tiple comparisons), who only showed minor delays in
finding the platform on day 2 compared to day 1
(Fig. 4a). The significant difference between the groups
in successfully adjusting to the novel platform location
on day 2 was also reflected in the percentage of direct
swim (DIM) pattern occurrences, which was significantly
higher in WT (50.00 ± 18.63) than in TG rats (26.79 ±
19.67, p = 0.0286, Mann–Whitney, Fig. 4b). Interestingly,
a change in swim pattern was observed in both groups
of rats between days 1 and 2 of the strategy shift para-
digm. While TG rats were using the chaining search
Fig. 3 Memory performance in probe trials across age memory recall performance was assessed in a probe trial 3 days after the completion of 16
acquisition trials, and no statistically significant difference was found between the genotypes at any age. The number of rats analyzed is stated in
each bar. a Probe trial, 3 months; b probe trial, 10 months; c probe trial, 13 months; d probe trial, 16 months
Fig. 4 Strategy shift performance in the Morris water maze. A significant effect of genotype was observed when assessing latency to find the
hidden platform (a). A lack of accurate learning and memory in TG rats was also reflected in TG rats exhibiting significantly less “direct swim”
patterns (DIM) during the learning of the novel platform location on day 2 (b). WT animals increased the use of a search strategy from day 1 to
day 2, while TG rats exhibited a decrease in the chaining search strategy (c)
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strategy (CSS) more than WT rats on day 1, this relation
reversed on day 2 (Fig. 4c). With TG rats using alterna-
tive swim patterns, WT rats seemed to show an appro-
priate adjustment by employing a search strategy more
often than TG rats.
TG rats show less exploratory behavior in the open field
arena
WT rats spent significantly more time actively exploring
an open field arena than TG rats at 3 months, a differ-
ence that persisted at 19 months of age (Mann–Whitney
test, Additional file 1: Figure S2).
TG rats develop widespread white matter inflammation
sooner than WT rats
OX-6-positive (MHC-II-expressing) cells are considered
activated microglia and are a vital component of neuroin-
flammation. The clear majority of OX-6 positive cells were
consistently observed within major white matter tracts,
such as the corpus callosum, the internal capsule, and the
anterior commissure (Fig. 5b-e). We confirmed that this
histopathology developed over time by screening the
brains of 3-month rats, which showed only sporadic OX-6
positive cells in any white matter tract (Fig. 5a). Due to
the sporadic pattern of staining OX-6 positive activated
microglia could not be accurately quantified in 3-month
rats. We did however quantify OX-6 positive activated
microglia in the corpus callosum and internal capsule of
15-month WT and TG rats. At 15 months of age, TG rats
displayed a significant increase in activated microglia in
both the corpus callosum and internal capsule compared
to WT rats (p < 0.05, two-way ANOVA, Tukey’s post hoc
test, Fig. 5b, d, e). By 19 months, the difference between
genotypes was no longer observed (Fig. 5c–e); however,
both WT and TG 19-month old rats demonstrated signifi-
cantly higher amounts of activated microglia in both the
corpus callosum and internal capsule compared to
15-month old WT and TG rats (p < 0.05, two-way
ANOVA, Tukey’s post hoc test, Fig. 5d, e).
To assess whether TG rats displayed increased levels
of total microglia, IBA-1 immunostaining was per-
formed, and white matter tracts and cortical regions
were analyzed (Fig. 6). A significant increase in IBA-1
positive microglia was observed in both 15 and
19-month TG rats within the internal capsule (p < 0.05,
two-way ANOVA, Tukey’s post hoc test, Fig. 6d, e),
while no genotype differences were observed within the
corpus callosum or cerebral cortex (Fig. 6f ).
Aged TG and WT rats show mild cortical inflammation
but no differences in cortical neuron loss or myelin
content
When screening brains for OX-6 signal patterns, mild accu-
mulations of OX-6 positive cells in the cortex were
observed (Fig. 7A, B; rating scale exemplified in B′). Cor-
tical activated microglia were present in aged WT and TG
rats to a similar extent. In order to find out whether the
white matter pathology and sporadic focal accumulation of
cortical activated microglia resulted in neuronal loss, we
quantified NeuN positive cells within the cortex of WT and
TG rats (Fig. 7C, D). At 15 months of age, there were no
statistically significant differences in NeuN-positive cells in
the cerebral cortex. Likewise, there were no statistical dif-
ferences between NeuN-positive cells in the cerebral cortex
of 19-month rats. To determine if the increase in activated
microglia present within the white matter tracts resulted in
demyelination, Luxol fast blue was performed in 3, 15, and
19-month-old rats (Additional file 1: Figure S3). Quantifica-
tion demonstrated no genotype- or age-related differences
in myelin content (Additional file 1: Figure S3).
Discussion
Sporadic AD has been difficult to model in laboratory ro-
dents, as they do not naturally develop hallmarks of AD,
such as amyloid plaques and neurofibrillary tangles. This
is emphasized by the fact that the expression of two APP
mutations by APP21 transgenic rats, each of which will re-
sult in familial AD in humans, does not result in amyloid
plaque formation in old APP21 transgenic rats [12]. The
expression of the APP transgene in these rats therefore
does not induce what can be considered “rat AD,” instead,
it merely renders these rats capable of developing AD-like
pathology when challenged [12, 13]. As demonstrated in
the present study, these rats do, however, present with
spontaneous cognitive deficits, especially executive func-
tion deficits such as working memory and strategy shift
ability. This finding supports accumulating evidence that
amyloid plaques themselves may not be a good indicator
of disease severity, and that soluble forms of amyloid may
indeed be more neurotoxic and clinically meaningful [21].
It is interesting that the transgene by itself does not seem
to produce a progressive deficit in spatial working mem-
ory or long-term memory, as measured here in the Morris
water maze task over the course of 19 months. Strategy
shift ability was only tested once at the end of the study,
which does not allow any conclusions as to the develop-
ment of this deficit over time. It should be noted that
when interpreting behavioral test results, Fisher 344 wild-
type rats are known to deteriorate cognitively in behav-
ioral tests as they age, and we can only measure the effect
of the transgene beyond the naturally occurring cognitive
decline of Fisher 344 rats [22–24]. Moreover, due to the
longitudinal design of the present study, rats are repeat-
edly exposed to the Morris water maze test and may be-
come familiar with it to the point where learning deficits
may have been masked, thereby underestimating the cog-
nitive deficit in the current design. Future investigations
will have to clarify whether APP21 transgenic rats show
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impairment specific to the Water maze test, or whether
other spatial tests, e.g., the Barnes maze, as well as
non-spatial learning and memory tasks, such as the novel
object recognition test, also precipitate a cognitive deficit
in these rats. Additionally, robust tasks such as set-shifting
tasks will allow for a better assessment of executive dys-
function in the APP21 rat.
In line with the naturally occurring aging process in
Fisher 344 rats, both WT and TG rats showed a clear
age-related progression of white matter inflammation as
Fig. 5 Activated microglia within white matter tracts: At 3 months of age, OX-6 positive activated microglia were sparse/rare within the corpus
callosum and internal capsule (a). At 15 months of age, significantly more OX-6 positive signal was found within the corpus callosum of TG than
WT rats (b). At 19 months of age, there were no statistical significant differences between activated microglia within the corpus callosum or
internal capsule between WT and TG rats (c). The amount of OX-6 positive microglia in both white matter tracts increased visibly at 15 months,
especially in TG rats (b). Activation of microglia in white matter continues to increase to 19 months of age, with comparable amounts in both
genotypes (c). Quantification of OX-6 positive activated microglia within the white matter tracts showed a significantly higher load in TG vs. WT
rats at 15 months, but not at 19 months in both the corpus callosum and (d) and internal capsule (e). Data is represented as group mean ± SEM.
An asterisk indicates statistical significance between WT and TG rats, the number sign indicates statistical significance between 15 and 19 months
WT or TG rats, respectively (p < 0.05, two-way ANOVA, Tukey’s post hoc test, n values indicated within bars on graphs)
Weishaupt et al. Journal of Neuroinflammation  (2018) 15:241 Page 8 of 12
measured by the presence of OX-6 positive, activated
microglia in the corpus callosum and in the internal cap-
sule. Based on the assessments at 15 and 19 months of
age, APP21 TG rats seem to develop this pathology earlier
than WT rats, but plateau so that both genotypes demon-
strate similar OX-6-positive microglia load at 19 months
of age. The presence of significantly increased white mat-
ter inflammation in TG rats compared to WT rats at
15 months of age suggests that TG rats are developing
histological pathology in line with a pre-dementia state in
humans earlier or more readily than wildtype rats do.
Combined with cognitive deficits, APP21 TG rats seem to
present a unique model of pre-AD pathology. This offers
a novel opportunity to study preventative strategies for de-
mentia in a pre-clinical rat model capable of undergoing
sophisticated behavioral tests [10].
Fig. 6 Total microglia analysis. IBA-1 positive microglia were assessed in 3 months (a), 15 months (b), and 19 months (c) WT and TG rats. Higher
magnification insets are from the (i) corpus callosum, (ii) internal capsule, and (iii) cerebral cortex. Quantification shows TG rats have increased
IBA-1 positive microglia in the internal capsule at 15 and 19 months of age (d), but no increased in IBA-1 positive microglia within the corpus
callosum (e) or cerebral cortex (f). An asterisk indicates statistical significance between WT and TG rats, (p < 0.05, two-way ANOVA, Tukey’s post
hoc test, n values indicated within bars on graphs)
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A limitation to this study is that only male rats were
investigated. It is possible that sexual dimorphisms exist
between males and females with respect to behavioral
responses as this has been reported in the past [25]. Fu-
ture work could investigate any sexual dimorphisms in
behavior and pathology in APP21 TG rats. Even so, the
fact that APP21 TG rats are sensitive to developing
more severe pathology when challenged, but only over
the course of several months, also mirrors the clinical
situation with regards to known non-genetic risk factors
for dementia in middle age, such as smoking, stroke,
and multiple concussions or traumatic brain injury [26],
Fig. 7 Cortical histopathology. Photomicrographs of cortical tissue sections from rats at different ages stained with OX-6 for activated microglia
(A). Rating scores of OX-6 positive signal revealed a slight increase in cortical signal from 15 to 19 months of age, but no statistically significant
genotype differences (B, rating score exemplified in B′). Photomicrographs of medial (left) and lateral (right) cortex sections stained for NeuN
positive neurons (C). No genotype difference or neuronal loss was observed after quantification of NeuN signal (D). Statistical analysis was
performed using a two-way ANOVA
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which have to our knowledge not been tested in this
model. All these features make the APP21 TG rat a
unique model for studying risk factors for AD.
Conclusions
We here provide behavioral and histopathological evi-
dence in support of APP21 TG rats being a novel clinic-
ally relevant model to study early correlates of cognitive
impairment. Widespread, diffuse white matter inflamma-
tion may point to white matter pathology as a prominent
pathological mechanism in early processes of cognitive
decline. Further studies are needed to elucidate how
white matter inflammation can progress to AD-like
histopathology when APP21 transgenic rats are chal-
lenged, and whether counteracting this early inflamma-
tory stage can prevent or delay neuropathology
consistent with neurodegenerative disease.
Additional file
Additional file 1: Figure S1 Morris water maze swim speed. Average
speed across learning trials is not statistically different between WT and
TG rats at any time point. Figure S2 Open field activity. TG animals spent
significantly less time ambulating in the arena during the 10 min test
period than WT counterparts at 3 months of age (A). Likewise, WT
animals exhibit significantly more rearing activity (B). At 19 months, TG
animals still spent significantly less ambulating than WT rats (C). Graphs
show mean ± SEM. One asterisk indicates p < 0.05, two asterisks indicate
p < 0.01 (Mann–Whitney test), n values indicated within graph bars.
Figure S3 Luxol fast blue histology. Photomicrographs of coronal rat brain
sections stained with Luxol fast blue from 3 months (A), 15 months (B),
and 19 months (C) WT and TG rats. Higher magnification insets are from
the (i) corpus callosum and (ii) internal capsule. Quantification in the
anterior corpus callosum (D), posterior corpus callosum (E), and internal
capsule (F) showed no significant differences in myelin content between
genotypes or age time points. Graphs show mean ± SEM, n values
indicated within graph bars. (DOCX 8940 kb)
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